Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

References

• Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–690.
   PubMed Web of Science ®Google Scholar
• Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–344.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–384.
   PubMed Web of Science ®Google Scholar
• Dudekula A, Rachakonda V, Shaik B, et al. Weight loss in nonalcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS One. 2014;9:e111808
   Google Scholar
• Chachay VS, Kirkpatrick CM, Hickman IJ, et al. Resveratrol-pills to replace a healthy diet? Br J Clin Pharmacol. 2011;72:27–38.
   PubMed Web of Science ®Google Scholar
• Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337–342.
   PubMed Web of Science ®Google Scholar
• Baur JA. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev. 2010;131:261–269.
   PubMed Web of Science ®Google Scholar
• Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612–622.
   PubMed Web of Science ®Google Scholar
• Heebøll S, Thomsen KL, Pedersen SB, et al. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol. 2014;6:188–198.
   PubMedGoogle Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
   PubMed Web of Science ®Google Scholar
• Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–1759.
   PubMed Web of Science ®Google Scholar
• Kazankov K, Møller HJ, Lange A, et al. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children. Pediatr Obes. 2015;10: 226–233.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Lymp J, Sauver JS, et al. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int. 2006;26:1209–1216.
   PubMed Web of Science ®Google Scholar
• Heebøll S, Thomsen KL, Clouston A, et al. Effect of resveratrol on experimental non-alcoholic steatohepatitis. Pharmacol Res. 2015;9596C:34–41.
   Web of Science ®Google Scholar
• Faghihzadeh F, Adibi P, Rafiei R, et al. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34:837–843.
   PubMed Web of Science ®Google Scholar
• Chachay VS, Macdonald GA, Martin JH, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12: 2092–2103.
   PubMed Web of Science ®Google Scholar
• Poulsen MM, Vestergaard PF, Clasen BF, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62: 1186–1195.
   PubMed Web of Science ®Google Scholar
• Yoshino J, Conte C, Fontana L, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012;16:658–664.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhao X, Ran L, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis. 2015;47: 226–232.
   PubMedGoogle Scholar
• de Ligt M, Timmers S, Schrauwen P. Resveratrol and obesity: can resveratrol relieve metabolic disturbances? Biochim Biophys Acta. 2015;1852:1137–1144.
   PubMed Web of Science ®Google Scholar
• Mendez-del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, et al. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014;12:497–501.
   PubMed Web of Science ®Google Scholar
• Tang PC, Ng YF, Ho S, et al. Resveratrol and cardiovascular health-promising therapeutic or hopeless illusion? Pharmacol Res. 2014;90:88–115.
   PubMed Web of Science ®Google Scholar
• Patel KR, Andreadi C, Britton RG, et al. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med. 2013;5:205ra133.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ma W, Zhang P, et al. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr. 2015;34:27–34.
   PubMed Web of Science ®Google Scholar
• Ørnstrup MJ, Harsløf T, Kjær TN, et al. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2014;99:4720–4729.
   PubMed Web of Science ®Google Scholar
• Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109–1122.
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang S, Zhao A, et al. Transcriptomic and metabonomic profiling reveal synergistic effects of quercetin and resveratrol supplementation in high fat diet fed mice. J Proteome Res. 2012;11:4961–4971.
   PubMed Web of Science ®Google Scholar
• Cottart CH, Nivet-Antoine V, Beaudeux JL. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res. 2014;58:7–21.
   PubMed Web of Science ®Google Scholar